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Abstract:  
The human embryonic stem cell line RCe013-A (RC-9) was derived under quality assured compliance 
with UK regulation, European Union Directives and International guidance for tissue procurement, 
processing and storage according to Good Manufacturing Practice (GMP) standards.  The cell line 
was derived from a failed to fertilise oocyte voluntarily donated as unsuitable and surplus to fertility 
requirements following informed consent.   RCe013-A (RC-9) shows normal pluripotency marker 
expression and differentiation to the three germ layers in vitro and in vivo.  It has a normal 46XY 
male karyotype and microsatellite PCR identity, HLA and blood group typing data are available.   
Resource table:  
Name of stem cell 
construct     
RCe013-A 
  
Alternative name RC-9, RC9 
  
Institution   Roslin Cells Ltd. 
  
Person who created 
resource   
B. Tye, K. Bruce, P. Dand, G. Russell, D.M.  Collins, A. Greenshields, J. 
Marshall, K. McDonald, H. Bradburn, M.A. Canham 
  
Contact person and 
email   
Paul.desousa@roslincells.com; Paul.desousa@ed.ac.uk 
Janet.downie@roslincells.com 
Aidan.courtney@roslincells.com 
Malcolm.bateman@roslinfoundation.com 
Tilo.kunath@ed.ac.uk 
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Date archived/stock 
date   
10 September 2014 (Seed lot, Passage 28) 
  
Type of resource   Biological reagent: cell line 
  
Sub-type   hESC, clinical grade 
  
Origin  Zygote (Oocyte/1PN) 
  
Key transcription 
factors   
Oct4 (confirmed by flow cytometry), 
  
Authentication   See Quality Control Certificate of Analysis (Fig. 1) 
  
Link to related 
literature (direct URL 
links and full 
references)   
N/A 
  
Information in public 
databases   
http://hpscreg.eu/cell-line/RCe013-A 
  
Ethics   Informed consent obtained.  Scotland A Research Ethics committee approval 
obtained (07/MRE00/56).  Conducted under the UK Human Fertilisation and 
Embryology Authority licence no R0136 to centre 0202 and UK Human Tissue 
Authority (HTA) licensing number 22631. 
 
Resource details 
RCe013-A (RC-9) was received as a failed to fertilise oocyte/1PN (pro-nuclear) embryo that was 
surplus to requirement or unsuitable for clinical use due to late development.   Human embryonic 
stem cell (hESC) isolation, expansion and qualification was performed in a facilities whose 
specification, operation and monitoring complied with GMP standards enabling; i) a fully traceable 
procurement procedure with informed ethical consent which includes provision for commercial use, 
ii) detailed medical history and blood borne virus (BBV) screening of donors, and iii) compilation of a 
cell line history providing details on hESC manufacturing process and quality control testing regime.  
Human ESC culture and processing was performed in a grade A tissue culture cabinet in a grade B 
clean room environment monitored for particulate and microbiological contamination during cell 
processing in accordance with Rules and Guidance for Pharmaceutical Manufacturers and 
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Distributors - The Orange Guide, compiled by the UK Medicines Healthcare Products Regulatory 
Authority (Go to: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-
distribution-practice). Accordingly, the facility was operating under a mature Quality Management 
System, compliant with ISO9001:2008 standards.  Further hESC derivation was performed under 
licensure from the UK HFEA (R0136 to centre 0202) and HTA (Licensing Number 22631).   
The embryo was grown to blastocyst stage and the cell line was derived by whole embryo outgrowth 
on mitotically inactivated human dermal fibroblast (HDF) feeder cells. HDFs were derived and 
manufactured according to GMP and had been approved for clinical use by the Food and Drug 
Administration, USA.  During derivation on HDFs, hESCs were grown in a xeno-free cell therapy grade 
media (XF KODMEM) supplemented with xeno-free human recombinant bFGF. HESCs were 
subsequently expanded in a GMP grade serum-free medium (StemPro hESC Serum Free Medium,) 
and xeno-free matrix (CellStart). The former contained bovine serum albumin (BSA) from a 
Transmissible Spongioform Encephalopathy (TSE)-free country of origin.  The cell line was 
cryopreserved in a GMP compliant cryopreservation solution (CryoStor CS10). 
By flow cytometry, RCe013-A (RC-9) expressed the pluripotency makers Oct-4, Tra-1-60 and SSEA-4 
(98.9%, 99.2% and 100.0%, respectively), whereas low expression of the differentiation marker 
SSEA-1 (3.0%) was observed (Fig. 1, Fig. 2).  Differentiation to the three germ layers, endoderm, 
ectoderm and mesoderm, was demonstrated using embryoid body formation in vitro, and 
expression of the germ layer markers α-fetoprotein, β-tubulin and muscle actin was observed (Fig. 3, 
top panel). In vivo teratoma formation yielded typical hESC derived teratomas.  Histological 
examination of fixed and stained sections clearly showed generation of cell types from ectoderm 
and mesoderm lineages.  Endoderm differentiation was also present, but the quality of the 
structures meant these could not be fully characterised (Fig. 3, bottom panels).  
A microsatellite PCR profile has been obtained for the cell line, and HLA Class I and II typing is 
available (Table 1).  Blood group genotyping gave the blood group BB (Table 1).  The cell line is free 
from mycoplasma contamination as determined by RT-qPCR.   
Verification and authentication  
The cell line was analysed for genome stability by G-banding and showed a normal 46XY male 
genotype (Fig. 4). SNP genotyping was carried out using the Illumina HumanCytoSNP-12 v2.1 
BeadChip and revealed a 120kb region deleted on chromosome 8q24.23 as described in Canham et 
al (2015).  In addition to containing no protein coding genes, this region has been observed many 
times in healthy individuals, occurring with a frequency of 3.85% as documented in the Database of 
Genomic Variants (MacDonald et al, 2014).   
Materials and methods 
Ethics  
Derivation of hESC from surplus to requirement and failed to fertilise/develop embryos was 
approved by The Scotland A Research Ethics Committee and local ethics board at participating 
fertility clinics and conducted under licence no R0136 from the UK HFEA with informed donor 
consent.  The processing and storage of hESC cells for human application was conducted under 
licence number 22631 from the UK Human Tissue Authority.  
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Cell culture 
Fresh embryos were cultured EmbryoAssist (Origio (Medicult), Denmark) until Day 3 and BlastAssist 
(Origio) after Day 3 of development.  Embryos were cultured at 36.5 - 37.5°C, 5.0 ± 0.5% CO2, 5.0 ± 
0.5% O2 in drops under paraffin oil (Origio) and transferred to fresh medium at least every 2-3 days.   
By Day 8 of development, embryos were placed in derivation conditions consisting of mitotically 
inactivated GMP grade neonatal human dermal fibroblasts (HDFs) (Forticell Biosciences, NJ, USA) on 
tissue culture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF, 2mM L-glutamine, 
1% MEM Non essential amino acids, 2% XF Growth Factor Cocktail, 0. 1mM β-mercaptoethanol 
(ThermoFisher Scientific, Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher 
Scientific).      When available, cell therapy system quality reagents were used.  If required, assisted 
hatching was performed by removing the zona pellucidae mechanically using Swemed cutting tools 
(Vitrolife, Göteborg, Sweden).   
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma grade FCS (GE Healthcare (PAA), 
Buckinghamshire, UK) and 2 mM L-glutamine (ThermoFisher Scientific).  HDF were mitotically 
inactivated using gamma irradiation at 50 Gy using a Gammacell Elite 1000 machine.  For use as a 
feeder layer, irradiated HDFs were plated at 50000 cells/cm2 in XF KODMEM medium supplemented 
with 80 ng/ml human bFGF (ThermoFisher Scientific).  Cells were cultured at 36.5 - 37.5°C, 5.0 ± 
0.5% CO2, 5.0 ± 0.5% O2 and 50% medium exchanged 6 days a week.   
The established cell line was expanded and banked using CellStart matrix and Stempro hESC Serum 
Free Medium (cell therapy system quality reagents, ThermoFisher Scientific).  This contained BSA 
from a TSE-free country of origin. Passaging was performed mechanically using an EZ passage tool 
(ThermoFisher Scientific).  hESC lines were expanded to 25-30 wells of a 6-well plate and 
cryopreserved in 0.5-1 ml Cryostor CS10 (Biolife Solution, Washington, USA) using an EF600-107  
controlled rate freezer (Grant Instruments, Cambridge, UK) before being stored in a -150°C freezer 
(Panasonic Biomedical, Loughborough, UK).   
Mycoplasma 
In process mycoplasma detection was performed using Applied Biosystems PrepSEQ™ Mycoplasma 
Nucleic Acid Extraction Kit and MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit (ThermoFisher 
Scientific (Applied Biosystems)) according to the manufacturer’s instruction. Eurpoean 
pharmacopoeia (EP) mycoplasma testing was carried out by Moredun Scientific Ltd. (Edinburgh, UK), 
under a quality and technical agreement.   
Endotoxin 
Endotoxin levels were determined using the Kinetic-QCL assay (Lonza) and an incubating plate 
reader (BioTek ELx808) according to the manufacturer’s instructions. Briefly, an unknown sample 
was compared with a standard curve of known levels of control endotoxin.  An assay was deemed 
valid if the coefficient of correlation, r ≥ 0.980 and the CV (%) for the standard curve was ≤10%, and 
the reaction time of the negative control was greater than the reaction time of the lowest standard 
on the standard curve.   
Flow cytometry  
Pluripotency was determined using the Human and Mouse Pluripotent Stem Cell Analysis kit (BD, 
Oxford, UK).   Oct 3/4 and SSEA-4 were included as pluripotency markers, and SSEA-1 as a 
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differentiation marker.   FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency 
marker.  Fixed and permeabilised cells were analysed using a FACS Aria flow cytometer (BD) or a 
Guava easyCyte flow cytometer (Millipore, Watford, UK).  Percentage expression of each marker was 
compared to isotype control or unstained cells.   
Viability 
Viability was determined using the Guava ViaCount assay.  Briefly, the Guava Viacount reagent 
(Millipore) containing a nuclear and a viability dye, was mixed with a single cell suspension, 
incubated for 5 minutes and analysed using the Guava easyCyte flow cytometer (Millipore).  Total 
cell count, viable cell count and percentage viable cells was obtained.   
In vitro differentiation 
hESCs were pre-treated for 1 h with 10 µM ROCK inhibitor in Stempro hESC SFM (ThermoFisher 
Scientific) and embryoid bodies (EBs) generated in ultra low attachment plates (Corning) for 7 days 
before being transferred into EB medium (20% FBS (GE Healthcare (PAA)), 80% KO-DMEM 1 mM L-
glutamine, 3.5 µM -mercaptoethanol, 1 % nonessential amino acids (all ThermoFisher Scientific)), 
on glass slide tissue culture chambers (Nunc, ThermoFisher Scientific) coated with 0.2% gelatin 
(Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days. 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde (ThermoFisher Scientific (Alfa Aesar)), permeabilised using 
100% ethanol (ThermoFisher Scientific) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000; 
Sigma) and muscle-specific actin (1:50; DAKO, Glostrup, Denmark) and secondary antibody anti 
mouse IgG-AlexaFluor 488 (1:200; Sigma).  Images were acquired using a Zeiss S100 Axiovert 
fluorescence microscope or Nikon eC1 confocal microscope 
In vivo differentiation 
The developmental potential of hESC lines to form teratomas consisting of tissues representative of 
all three germ layers was evaluated following transplantation under kidney capsule in NOD scid 
gamma mice.   After three months, the animals were culled and assessed for teratoma formation.  
Teratomas were fixed in 4% paraformaldehyde, embedded in paraffin wax and serial sections of 7μm 
thickness were cut according to standard procedures.  For histological assessment, the tissue 
sections were dewaxed, rehydrated and stained with Masson staining.  Tissue sections were 
analysed using bright field and microscopy and digital images were recorded.   
SNP Genotyping and Analysis  
DNA samples were assayed using the Illumina HumanCytoSNP-12 v2.1 BeadChip. Genotyping data 
was initially assessed using GenomeStudio genotyping module (v1.94, Illumina).  Karyostudio (v1.4, 
Illumina) was employed to perform automatic normalisation and to identify genomic aberrations 
utilising default settings of the built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele 
frequency and smoothened Log R ratio plots for detected regions. These parameters are designed to 
detect CNVs greater than 75 kb and CN-LOH regions larger than 1 MB with a confidence value 
greater than 35. All identified regions were first cross-matched to the Database of Genomic Variants 
(DGV; http://dgv.tcag.ca) to identify naturally-occurring structural variations in the human. CNVs 
that were not identified on the DGV were then checked against a list of ES cell-associated culture 
adaptation genomic variants published by the International Stem Cell Initiative (Amps et al, 2011).  
See also Canham et al, 2015 for further details.  
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Genomic analysis and outsourced assays 
All outsourced assays were carried out under a Quality and Technical Agreement.  DNA was 
extracted using the QIAamp DNA Mini kit (Qiagen, Manchester, UK) according to manufacturer’s 
recommendations and provided in recommended quantities to the service providers.     
Microsatellite PCR, or Short Tandem Repeat analysis, was used to determine cell line identity and 
was carried out by Public Health England.   A profile was obtained for the following core alleles: 
vWA, D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.   
Human Leukocyte Antigen (HLA) tissue typing was carried out by the Scottish National Blood 
Transfusion Service. 
Blood group genotyping was carried out by the Molecular Diagnostics laboratory at NHSBT. 
Karyotype analysis was carried out by The Doctors Laboratory (London, UK) or the Western General 
Cytogenetics Laboratory (Edinburgh, UK).  Live cells at 60-70% confluency were shipped in warm 
containers, fixed and analysed by standard G-banding analysis.  For clinical grade lines, 30 spreads 
were analysed.    
Viral screening for cytomegalovirus (CMV), Human T-cell lymphotropic virus (HTLV), Human 
immunodeficiency virus (HIV)-1, Hepatitis C virus (HCV), Hepatitis B virus (HBV), Epstein-Barr virus 
(EBV) and syphilis was carried out by The Doctors Laboratory.   
Eurpoean pharmacopoeia (EP) sterility testing was carried out by Moredun Scientific Ltd. using the 
culture method.    
Figures and tables  
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Fig. 1.  Quality Control Certificate of Analysis for RCe013-A (RC-9) P28 seed lot.   
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Fig. 2.  RCe013-A (RC-9) was subjected to flow cytometry analysis for markers of pluripotency with 
specific antibody (top row) or isotype control (bottom row) as indicated above the dot plot. 
Percentage staining is indicated in the respective quadrants.  This analysis was carried out at passage 
31 during re-banking of the cell line.   
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Fig. 3.  RCe013-A (RC-9) can differentiate into the three germ layers in vitro and in vivo.  Embryoid 
body mediated differentiation (top panel) resulted in expression of β-tubulin III (ectoderm), muscle 
actin (mesoderm), and α-fetoprotein (endoderm).  Specific staining is shown in green, cell nuclei are 
counterstained with DAPI (blue).  Histological sections of teratomas formed under the kidney 
capsule of mice yielded clear evidence for mesoderm and ectoderm differentiation and indicated 
that endoderm structures were also present.  Tissue structures identified are indicated by arrows.   
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Fig. 4.  RCe013-A (RC-9) at passage 28 was analysed by Giesma staining of 30 metaphase spreads and 
showed a normal 46XY male karyotype at banking.   
Table 1.  Microsatellite PCR, blood group and HLA tissue typing results for RCe013-A (RC-9).   
Microsatellite PCR results 
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2 
15 16 15 18 12 12 18 23 
        Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2 
X Y 13 15 30.2 32.2 13 22 
        D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2 
14 15 6 10 20 20 10 10 
        D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2 
10 13 9 12 12 13 8 8 
        
Blood group genotyping 
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA 
pos pos pos neg pos neg pos neg 
        Jka Jkb K k  M N S  s 
neg pos neg pos pos pos pos pos 
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        Kp a Kp b Do a Do b ABO 
   neg pos neg pos BB 
   
        
HLA tissue typing 
HLA Class I Type HLA-A*01, A*02; B*07, B*08; Cw*07 
HLA Class II Type HLA-DRB1*01, DRB1*15; DRB5*01; DQB1*05, DQB1*06 
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